Articles Vol. 67 No. CĐ2-NCKH 05/03/2026

A STUDY ON THE CLINICAL CHARACTERISTICS AND TREATMENT ADHERENCE IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE AT LE VAN THINH HOSPITAL

Nguyen Hong Van1,2,3,4, Nguyen Trong Thu2,4, Huynh Giao2,4, Nguyen Thanh Duc1,3
1 Hong Bang International University
2 Le Van Thinh Hospital
3 Trường Đại học Quốc tế Hồng Bàng
4 Bệnh viện Lê Văn Thịnh
DOI: 10.52163/yhc.v67iCD2.4421
23 Views
11 Downloads
Keywords
Gastroesophageal reflux disease, GERD, treatment adherence, MMAS-8.
Abstract

Objective: To investigate clinical and paraclinical characteristics, treatment adherence rates, and related factors in patients with gastroesophageal reflux disease at Le Van Thinh Hospital.

Methods: A cross-sectional descriptive study was conducted on 303 outpatients aged 18 and older diagnosed with gastroesophageal reflux disease. Data on demographics, clinical and paraclinical characteristics, and treatment adherence using the MMAS-8 scale were collected. Multivariate logistic regression analysis was used to identify factors associated with adherence.

Results: Females predominated (56.4%) with a mean age of 47.8 years. Clinically, heartburn accounted for 59.7% and regurgitation for 48.8%. Endoscopically, non-erosive reflux disease accounted for the majority (74.3%). The overall treatment adherence rate (medium and high) was 64%. 4 independent factors significantly reduced treatment adherence: increased total daily pill count (OR = 0.79; p = 0.002), presence of anxiety/depression (OR = 0.49; p = 0.028), concomitant other gastrointestinal diseases (OR = 0.48; p = 0.021), and presence of regurgitation symptoms (OR = 0.43; p = 0.015).

Conclusion: The majority of patients presented with typical clinical manifestations, although most cases were classified as non-erosive reflux disease. Treatment adherence was generally moderate. Optimizing pill burden and attending to mental health are necessary to improve treatment efficacy.

References
[1]
Boulton K.H.A, Dettmar P.W. A narrative review of the prevalence of gastroesophageal reflux disease (GERD). Ann of Esophagus, 2021, 5. doi: 10.21037/aoe-20-80. Google Scholar
[2]
Wiesner A, Zwolińska-Wcisło M, Paśko P. Effect of food and dosing regimen on safety and efficacy of proton pump inhibitors therapy - A literature review. Int J Environ Res Public Health, 2021, 18 (7): 3527. doi: 10.3390/ijerph18073527. Google Scholar
[3]
Hoàng Thy Nhạc Vũ, Trần Văn Khanh. Đặc điểm mô hình bệnh tật Bệnh viện Lê Văn Thịnh giai đoạn 2018-2023. Tạp chí Y học cộng đồng, 2024, 65 (CĐ6): 24-33. doi: 10.52163/yhc.v65iCD6.1349. Google Scholar
[4]
Lê Thị Thanh Thủy, Lê Thị Xuân Thảo. Tuân thủ điều trị tiệt trừ Helicobacter pylori ở bệnh nhân viêm loét dạ dày-tá tràng. Tạp chí Y học thành phố Hồ Chí Minh, 2017, 21 (2): 251-258. Google Scholar
[5]
Xie F, Yang B, Yan Z et al. Global temporal trends and projections of gastroesophageal reflux disease prevalence: Age-period-cohort analysis 2021. PLoS One, 2025, 20 (11): e0334396. doi: 10.1371/journal.pone.0334396. Google Scholar
[6]
Quach D.T, Phan B.T. A long duration of reflux symptoms is the predominant risk factor for depression in Vietnamese patients with gastroesophageal reflux disease. Neuropsychiatr Dis Treat, 2022, 18: 2141-2150. doi: 10.2147/NDT.S381892. Google Scholar
[7]
Wang H, Qu Y, Lin Y et al. Helicobacter pylori infection and eradication in relation to gastroesophageal reflux disease. J Gastroenterol Hepatol, 2025, 40 (10): 2391-2401. doi: 10.1111/jgh.70009. Google Scholar
[8]
Kishor R, Kumari S et al. An assessment of treatment compliance using the Morisky scale-8 tool in adult hypertensive patients of Eastern India. J Family Med Prim Care, 2024, 13 (3): 924-931. doi: 10.4103/jfmpc.jfmpc_1416_23. Google Scholar
[9]
Puig-Moltó M, Lumbreras B, López-Pintor E. Improving proton-pump inhibitor adherence intervention between primary care and community pharmacies: A pre-post intervention study. Patient Prefer Adherence, 2024, 18: 2569-2580. doi: 10.2147/PPA.S485307. Google Scholar
[10]
He M, Wang Q et al. Association between psychosocial disorders and gastroesophageal reflux disease: A systematic review and meta-analysis. J Neurogastroenterol Motil, 2022, 28 (2): 212-221. doi: 10.5056/jnm21044. Google Scholar
[11]
Cassell B, Gyawali C.P et al. Beliefs about GI medications and adherence to pharmacotherapy in functional GI disorder outpatients. Am J Gastroenterol, 2015, 110 (10): 1382-1387. doi: 10.1038/ajg.2015.132. Google Scholar
[12]
Mermelstein J, Chait Mermelstein A, Chait M.M. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol, 2018, 11: 119-134. doi: 10.2147/CEG.S121056. Google Scholar